Q3 2025 RCC Market Sees an Expanded Campaign Theme, Shifting Formats and Delivery Methods, and Pipeline Progress

The Q3 2025 renal cell carcinoma market observed several notable developments, including new themes, formats, and early-stage pipeline coverage, with materials continuing to target healthcare professionals through digital channels.

Exelixis spotlighted the strong TRx performance of Cabometyx as well as maintained prescriber preference in combination with Opdivo for first-line RCC.

Arcus Biosciences planned a monotherapy data presentation for casdatifan in late-line RCC.

CRISPR promoted the development of CTX131, a CD70-targeting CAR-T cell therapy, for solid tumors.

New packaging and NDCs for Fotivda were introduced, along with an updated NCCN recommendation for RCC.

Keytruda Qlex’s FDA approval was announced, highlighting short administration time and comparable data to IV pembrolizumab.

Kura Oncology showcased events to present preclinical FTI combination data and to review the first clinical data for KO-2806.

Opdivo Qvantig’s “Faster” campaign expanded into DTC audiences, highlighting the time-saving benefits of SC delivery.